Sheppard advises pharma, biotech, and medical device companies on IP, corporate finance, and FDA regulatory matters across the product lifecycle. The firm works with clients developing technologies such as gene and cell therapies, CAR-T treatments, immunotherapies, antibody-drug conjugates, and other biologics. In New York, Jeffrey Fessler co-leads the life sciences team and focuses his practice on the biotechnology industry, while Scott Liebman also co-leads the team and heads the FDA regulatory and compliance practice, advising manufacturers on regulatory strategy. Fellow co-leader Lorna Tanner advises on IP protection and portfolio strategy from San Francisco.
Legal 500 Editorial commentary
Key clients
- Pacira Biosciences Inc.
- Tharimmune, Inc.
- Structure Therapeutics
- DNA Holdings Venture, Inc.
- Cytokinetics
- Gilead Sciences, Inc.
- California Institute of Technology
- TJ Biopharma
- Amarin Pharmaceuticals Ireland Limited
- Kite Pharma
- Achieve Life Sciences
- Vir Biotechnology (Vir)
- ShiraTronics
- Grail
- Unicycive Therapeutics, Inc.
- Cardiff Oncology, Inc.
- Celularity Inc.
- LaNova Medicines
- Sanara MedTech, Inc.
- TriSalus Life Sciences
Work highlights
Obtained multiple federal rulings in favor of Pacira, supporting its claims against competitors that involve issues of first impression under the Lanham Act and Federal Food, Drug, and Cosmetic Act (FDCA).
Represented Tharimmune, Inc. (NASDAQ: THAR), in its approximately $540 million private placement.
Advised DNA Holdings Venture, Inc., as the strategic advisor and investor to Predictive Oncology Inc.’s (Nasdaq: POAI) major private placement transactions totaling $344.4 million.
Practice head
Jeffrey Fessler; Scott Liebman; Lorna Tanner